CRVS Corvus Pharmaceuticals Inc gains 26% Sep 20, 2017

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California. http://www.priceseries.com/trade/CRVS-Corvus-Pharmaceuticals-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2017082320170920.html